The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ARE Th2 HELPER T LYMPHOCYTES BENEFICIAL, DELETERIOUS, OR IRRELEVANT IN PROMOTING ALLOGRAFT SURVIVAL?1
Abstract
It is widely accepted that Th1 helper T lymphocytes (HTL)* initiate allograft rejection by promoting the development of alloantigen-specific cytotoxic T lymphocytes (CTL) and delayed-type hypersensitivity (DTH) responses. Since Th2 HTL are antagonistic to Th1 development and function, a popular hypothesis states that preferential induction of allograft-specific Th2 would down-regulate Th1-driven rejection responses, thereby promoting allograft acceptance. This possibility would have direct application to clinical transplantation, in that preferential induction of Th2 may be accomplished by cytokine manipulation both in vitro and in vivo. While attractive, this hypothesis has not been rigorously tested, and the majority of evidence that supports or refutes its premises is associative in nature. In this Overview, studies that associate allograft-specific Th2 with both beneficial and deleterious responses are summarized, and recent studies aimed at preferential induction of allograft-specific Th2 through cytokine manipulation are discussed. THE Th1/Th2 PARADIGM HTL regulate the nature of an immune response by the profile of the cytokines they secrete. In both mouse and man, polarized HTL phenotypes have been described that produce discrete profiles of cytokines, and production of selected cytokine profiles has been associated with a variety of disease states (reviewed in 1). Th1 HTL produce interleukin (IL) 2, interferon (IFN)-γ, and lymphotoxin, which promote CTL development, DTH responses, and IgG2a antibody isotype switching, which facilitates antibody-dependent cellular cytotoxicity (ADCC). Therefore, Th1 promote cellular immune responses that are believed to serve as terminal effector mechanisms in allograft rejection (reviewed in 2). Th2 HTL produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13, thereby promoting humoral, allergic, and mucosal responses (1). As discussed below, Th1 and Th2 perpetuate their own development and are antagonistic to one another. Since Th2 are inhibitory to the development and function of Th1, it has been proposed that preferential induction of allograft-specific Th2 would inhibit Th1-regulated rejection responses, allowing a reduction or elimination of conventional immunosuppression. Further, an early Th1 → Th2 shift would be expected to decrease the number and severity of acute rejection episodes that are believed to contribute to the development of chronic rejection. Hence, cytokine manipulation represents an attractive, albeit speculative, therapeutic approach aimed at favoring the development of tolerogenic Th2. However, several aspects of this hypothesis must hold true if cytokine-based therapies are to have utility in transplantation: Are Th1-regulated effector mechanisms (CTL, DTH, ADCC) the only culprits in graft rejection? Are Th2 also capable of promoting CTL-, DTH-, and ADCC-mediated rejection? Do Th2 promote the development of alternate effector mechanisms that may surface in the absence of classical Th1-regulated responses? Are behaviors of Th1 and Th2 that have been defined primarily in in vitro systems operative during in vivo alloimmune responses? The answers to these questions are emerging, and the picture appears more complex than we might like. CYTOKINE MANIPULATION AND THE INDUCTION OF Th1 AND Th2 Th1 and Th2 subsets are thought to derive from a third phenotype, Th0, which produces a combination of cytokines characteristic of both Th1 and Th2 (1). The pattern of cytokines present during the initial stimulation of precursor cells dictates whether Th0 will preferentially develop into polarized Th1 or Th2. For example, Gajewski et al. (3) demonstrated that the presence of IFNγ during in vitro stimulation results in the development of T cells that produce IFNγ, but not IL-4, upon restimulation. Likewise, Swain et al. (4) found that the presence of IL-4 causes precursor cells to give rise to HTL that produce IL-4 and IL-5, but little or no IL-2 or IFNγ. Finkelman et al. (5) reported that in vivo neutralization of IFNγ promotes an antibody isotype shift from IgG2a (IFNγ regulated) to IgG1 (IL-4 regulated) when mice are challenged with the Th1-inducing pathogen Brucella abortus. Likewise, in vivo treatment with anti-IL-4 monoclonal antibodies (mAb) ablates the Th2-regulated IgE response to Nippostrongylus brasiliensis(6). Hence, cytokine profiles may be manipulated to influence Th1/Th2 balance, both in vitro and in vivo. IL-12 represents a key regulatory cytokine that promotes Th1 and inhibits Th2 differentiation (reviewed in 7). Indeed, neutralizing endogenous IL-12 converts Th1-dominated responses to Th2, while administration of exogenous IL-12 converts Th2 responses to Th1 in vivo (8). IL-12 is produced by stimulated antigen-presenting cells (APC), and its production is up-regulated by IFNγ and granulocyte-macrophage colony-stimulating factor. IL-12 up-regulates IFNγ production by T cells and natural killer cells which, in turn, promotes the development of polariz
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL‐4 directs the development of Th2‐like helper effectors
Swain, S. L., Weinberg, A. D., English, M., & Huston, G. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.11.3796 · Cited by 1,254
Cited by
Immune response to biologic scaffold materials
Badylak, S. F., & Gilbert, T. W. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2007.11.003 · Cited by 857
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Xenogeneic extracellular matrix as a scaffold for tissue reconstruction
Badylak, S. F. (2004) · Transplant Immunology · doi:10.1016/j.trim.2003.12.016 · Cited by 747
Extracellular matrix as an inductive scaffold for functional tissue reconstruction
Brown, B. N., & Badylak, S. F. (2014) · Translational Research · doi:10.1016/j.trsl.2013.11.003 · Cited by 516
The Host Immune Response to Tuberculosis
SCHLUGER, N. W., & ROM, W. N. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.3.9708002 · Cited by 428
Metadata
- Authors
- Piccotti, J. R., Chan, S. Y., VanBuskirk, A. M., Eichwald, E. J., & Bishop, D. K.
- Venue
- Transplantation
- Published
- 1997-03
- Volume
- 63
- Issue
- 5
- Pages
- 619-624
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2088031551
- Cited by
- 165
- References
- 1
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ARE Th2 HELPER T LYMPHOCYTES BENEFICIAL, DELETERIOUS, OR IRRELEVANT IN PROMOTING ALLOGRAFT SURVIVAL?1. https://app.cochat.ai/papers/10.1097/00007890-199703150-00001
- The paper
- Piccotti, J. R., Chan, S. Y., VanBuskirk, A. M., Eichwald, E. J., & Bishop, D. K. (1997). ARE Th2 HELPER T LYMPHOCYTES BENEFICIAL, DELETERIOUS, OR IRRELEVANT IN PROMOTING ALLOGRAFT SURVIVAL?1. Transplantation. https://doi.org/10.1097/00007890-199703150-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.